tradingkey.logo

Unicycive Therapeutics Inc

UNCY
View Detailed Chart

4.115USD

+0.025+0.61%
Market hours ETQuotes delayed by 15 min
58.07MMarket Cap
LossP/E TTM

Unicycive Therapeutics Inc

4.115

+0.025+0.61%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.61%

5 Days

-6.69%

1 Month

-7.11%

6 Months

+574.70%

Year to Date

+418.13%

1 Year

+944.42%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts
BUY
Current Rating
63.125
Target Price
1450.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

553
Total
5
Median
6
Average
Company name
Ratings
Analysts
Unicycive Therapeutics Inc
UNCY
8
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
27
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(7)
Neutral(3)
Buy(2)
Indicators
Sell(3)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.100
Neutral
RSI(14)
46.149
Neutral
STOCH(KDJ)(9,3,3)
27.221
Sell
ATR(14)
0.306
High Vlolatility
CCI(14)
-83.021
Neutral
Williams %R
79.279
Sell
TRIX(12,20)
-0.248
Sell
StochRSI(14)
3.338
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
4.314
Sell
MA10
4.239
Sell
MA20
4.337
Sell
MA50
4.233
Sell
MA100
2.422
Buy
MA200
1.520
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Ticker SymbolUNCY
CompanyUnicycive Therapeutics Inc
CEODr. Shalabh Gupta, M.D.
Websitehttps://unicycive.com/
KeyAI